No Data
No Data
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
UCB Gets Expanded FDA Approval for Psoriasis Drug Bimzelx
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
Leerink Partners Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
Jefferies Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $65